MAPT and Alzheimer disease: Another phase II combination trial planned to start soon is the Alzheimer's Tau Platform (ATP), which aims to evaluate the safety, tolerability, and effects on tau biomarkers of two distinct tau regimens in individual with preclinical and prodromal AD [18].